In addition, SOLARIS (Period 1) and Phase 1 safety results demonstrated no incidence of post-injection delirium/sedation syndrome (PDSS) in participants taking TEV-'749 to date. The overall safety ...
Some results have been hidden because they may be inaccessible to you